Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 318 across all filing types
Latest filing 2026-02-27 Director's Dealing
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Director's Dealing Classification · 95% confidence The document is a short announcement regarding a transaction by a person discharging managerial responsibilities (PDMR). While it mentions a transaction, it is a notification of a director's dealing. According to the classification definitions, reports of personal share transactions by company directors are classified as DIRS.
2026-02-27 English
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
Director's Dealing Classification · 100% confidence The document title explicitly mentions 'Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated', which is the standard regulatory terminology for 'Director's Dealing' or 'PDMR' filings. The document is short and serves as an announcement of these transactions, fitting the definition for DIRS.
2026-02-18 English
Oculis Appoints Katie Kazem as Chief Legal Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Legal Officer (Katie Kazem) at Oculis Holding AG. This falls under the category of board or management changes, which is classified as MANG.
2026-02-17 English
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a press release from Oculis announcing that the company will be presenting at the 2026 J.P. Morgan Healthcare Conference. It details the company's pipeline, clinical trial milestones, and market opportunities. While it contains investor-relevant information, it is a standard corporate announcement regarding an upcoming presentation rather than a formal investor presentation deck itself, a quarterly report, or a regulatory filing. It fits the definition of a general regulatory announcement or corporate news release, which falls under the RNS category.
2026-01-08 English
Oculis tilkynnir um að Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hafi veitt Privosegtor stöðu byltingarkennds meðferðarlyfs til meðhöndlunar á sjóntaugabólgu
Regulatory Filings Classification · 95% confidence The document is a press release from Oculis Holding AG announcing that the FDA has granted 'Breakthrough Therapy Designation' to their drug candidate, Privosegtor. It details the clinical trial results (ACUITY), the regulatory status, and future development plans (PIONEER program). This is a standard corporate announcement regarding regulatory milestones and product development, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like earnings releases or financial reports.
2026-01-06 Icelandic
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
Regulatory Filings Classification · 95% confidence The document is a press release issued by Oculis Holding AG announcing that the U.S. FDA has granted 'Breakthrough Therapy Designation' to their drug candidate, Privosegtor. It details the clinical trial results (ACUITY trial), the regulatory status, and the company's future development plans. This is a standard corporate announcement regarding regulatory milestones and business developments, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into more specific categories like Earnings Release (no financial results/EPS), M&A, or Dividend announcements.
2026-01-06 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.